Compare Stocks → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CGTXNASDAQ:ELEVNASDAQ:GMDANASDAQ:LJPCNYSE:RCOR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$1.84-3.2%$1.96$0.90▼$3.49$71.76M1.63201,436 shs99,177 shsELEVElevation Oncology$4.01-3.1%$4.14$0.36▼$5.89$195.09M1.342.71 million shs318,832 shsGMDAGamida Cell$0.02-8.2%$0.26$0.03▼$2.51$2.40M0.939.20 million shs2.20 million shsLJPCLa Jolla Pharmaceutical$5.73$3.07▼$6.24$155.11M2.39158,476 shs66,708 shsRCORRenovacor$3.20$3.07$1.34▼$9.74$55.26M-0.2830,033 shsN/AThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics+0.53%-4.04%+2.15%-17.39%+11.10%ELEVElevation Oncology-5.69%-10.00%-5.05%+51.09%+116.75%GMDAGamida Cell+14.09%-15.00%-95.41%-92.92%-98.99%LJPCLa Jolla Pharmaceutical0.00%0.00%0.00%0.00%0.00%RCORRenovacor0.00%0.00%0.00%0.00%0.00%Bitcoin Rockets To Record High But Buy THIS Instead (Ad)Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGTXCognition Therapeutics3.455 of 5 stars3.55.00.00.03.34.20.0ELEVElevation Oncology1.9883 of 5 stars3.52.00.00.01.92.50.6GMDAGamida Cell0.5836 of 5 stars3.42.00.00.00.00.80.0LJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGTXCognition Therapeutics3.00Buy$6.67262.32% UpsideELEVElevation Oncology3.00Buy$7.2580.80% UpsideGMDAGamida Cell2.75Moderate Buy$4.7530,348.72% UpsideLJPCLa Jolla PharmaceuticalN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/ACurrent Analyst RatingsLatest RCOR, GMDA, LJPC, CGTX, and ELEV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/28/2024CGTXCognition TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/27/2024CGTXCognition TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.003/7/2024ELEVElevation OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$7.003/7/2024ELEVElevation OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$5.00 ➝ $8.003/7/2024ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/1/2024ELEVElevation OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.002/20/2024ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.50 ➝ $6.001/29/2024GMDAGamida CellJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGTXCognition TherapeuticsN/AN/AN/AN/A$0.76 per shareN/AELEVElevation OncologyN/AN/AN/AN/A$1.29 per shareN/AGMDAGamida Cell$1.78M1.35N/AN/A($0.02) per share-0.78LJPCLa Jolla Pharmaceutical$75.72M0.00N/A7.95($2.94) per share0.00RCORRenovacorN/AN/AN/AN/A$2.47 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGTXCognition Therapeutics-$25.79M-$0.86N/AN/AN/AN/A-83.48%-63.07%5/2/2024 (Estimated)ELEVElevation Oncology-$45.70M-$1.53N/AN/AN/AN/A-72.76%-43.15%5/20/2024 (Estimated)GMDAGamida Cell-$63M-$0.63N/A∞N/AN/AN/A-57.59%5/20/2024 (Estimated)LJPCLa Jolla Pharmaceutical$19.66M$0.1251.840.00N/A8.54%-5.46%4.00%N/ARCORRenovacor-$14.10M-$0.73N/AN/AN/AN/A-62.88%-48.90%N/ALatest RCOR, GMDA, LJPC, CGTX, and ELEV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023CGTXCognition Therapeutics-$0.38-$0.27+$0.11-$0.27N/AN/A3/6/2024Q4 2023ELEVElevation Oncology-$0.21-$0.19+$0.02-$0.19N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGTXCognition TherapeuticsN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGTXCognition TherapeuticsN/A3.373.37ELEVElevation Oncology0.5521.2221.22GMDAGamida Cell213.142.162.09LJPCLa Jolla PharmaceuticalN/A4.023.52RCORRenovacorN/A6.606.60OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGTXCognition Therapeutics43.35%ELEVElevation Oncology83.70%GMDAGamida Cell50.34%LJPCLa Jolla Pharmaceutical97.06%RCORRenovacor45.84%Insider OwnershipCompanyInsider OwnershipCGTXCognition Therapeutics23.80%ELEVElevation Oncology14.90%GMDAGamida Cell3.40%LJPCLa Jolla Pharmaceutical36.30%RCORRenovacor14.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCGTXCognition Therapeutics2539.00 million29.72 millionNot OptionableELEVElevation Oncology2948.65 million41.40 millionOptionableGMDAGamida Cell143154.05 million143.70 millionOptionableLJPCLa Jolla Pharmaceutical6124.94 million15.89 millionOptionableRCORRenovacor1917.27 million14.78 millionNot OptionableRCOR, GMDA, LJPC, CGTX, and ELEV HeadlinesSourceHeadlineNews of Recordnewsandsentinel.com - March 30 at 4:05 AMNHL opening night delivers record viewership on ESPNnhl.com - November 6 at 5:27 PMState Pension payments worth over £2,000 each month for older people living in these European countriesdailyrecord.co.uk - October 30 at 1:55 PMThe best early Black Friday turntable deals 2023whathifi.com - October 29 at 12:00 AMAnas Sarwar 'unhappy' with Keir Starmer over Labour leader's response to Gaza crisisdailyrecord.co.uk - October 27 at 2:36 PMNYC shoplifting hit record highs last year: ‘We can’t stop them’nypost.com - October 24 at 1:35 PMTranscriptional control of the inflammatory responsenature.com - October 18 at 7:59 AMRockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directorsfinance.yahoo.com - October 17 at 7:56 AMFolwell criticizes fellow Republicans on public records rollbackwral.com - October 14 at 8:16 PMBest Bluetooth turntables 2023: wireless record players for streaming vinylwhathifi.com - October 11 at 12:09 PMHere’s why you shouldn’t record meltdowns on an airplane: FAA insidernypost.com - October 3 at 11:57 PMRecord-breaking heat wave peaking in Eastern U.S. with highs near 100washingtonpost.com - September 28 at 6:28 PMiOS 17: How to Record a FaceTime Video or Audio Messagemacrumors.com - September 15 at 7:16 PMThis was the world’s hottest summer on record ‘by a large margin’washingtonpost.com - September 9 at 6:12 PMCapCut breaths life into new-wave blogging for modern businessesdailyrecord.co.uk - September 6 at 9:28 AMMontauk trailer listing eyes record — even with a price cuttherealdeal.com - September 5 at 11:26 PMRecord-Breaking Summer: Portland, New Orleans Break Daily High Temperature Records After Hottest July Everforbes.com - August 23 at 10:13 AMRecord-Breaking Summer: Jacksonville, Miami Break Daily High Temperature Records, After Hottest July Everforbes.com - August 16 at 6:56 PMPhoenix, New Orleans, Baton Rouge Break Daily High Temperature Records: Here’s Where Else Daily Records Have Fallenforbes.com - August 11 at 7:09 PMPhoenix, Dallas, Little Rock Break Daily High Temperature Records: Here’s Where Else Daily Records Have Fallenforbes.com - August 9 at 12:55 AMPhoenix just posted the hottest month ever observed in a U.S. citywashingtonpost.com - August 5 at 9:27 AMAcademic Recordsdrexel.edu - July 27 at 12:31 AMAfter Earth's hottest week on record, extreme weather surprises everyone — even climate scientistscbc.ca - July 25 at 5:27 PMRecord Highgrist.org - July 22 at 5:01 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCognition TherapeuticsNASDAQ:CGTXCognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.Elevation OncologyNASDAQ:ELEVElevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in New York, New York.Gamida CellNASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.La Jolla PharmaceuticalNASDAQ:LJPCLa Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.RenovacorNYSE:RCORRenovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.